Numerous HBV Core Assembly Inhibitor classes were identified in an HTS campaign, using an in vitro infection model. Most promising candidate molecules are currently undergoing optimization with the use of molecular docking studies and rational drug design. Lead candidates will enter preclinical development in Q1 of 2016.